SCHEMBL5809135

SCHEMBL5809135

COc1cccc(-c2nnn[nH]2)c1OC

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.47
MGAM O43451 1/20 0.47
SI P14410 1/20 0.47
MGAM2 Q2M2H8 1/20 0.47
FGFR1 P11362 2/20 0.44
FGFR2 P21802 2/20 0.44
KDM4E B2RXH2 3/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
RAB9A P51151 2/20 0.40
NPSR1 Q6W5P4 1/20 0.40
PKM P14618 1/20 0.40
P2RX7 Q99572 2/20 0.40
ALDH1A1 P00352 2/20 0.40
TDP1 Q9NUW8 1/20 0.40
TP53 P04637 3/20 0.39
MAPT P10636 2/20 0.39
HSD17B10 Q99714 2/20 0.39
NPC1 O15118 1/20 0.39
ADORA2A P29274 1/20 0.38
POLB P06746 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3394704 0.85 ALDH1A1 (0.53) GAAKDM4EALDH1A1MAPTHSD17B10
SCHEMBL17207241 0.84 CTSA (0.36) GAAMGAMSIMGAM2FGFR1
SCHEMBL20377717 0.82 ALDH1A1 (0.46) GAAKDM4EALDH1A1MAPTHSD17B10
SCHEMBL9700721 0.80 FGFR1 (0.41) GAAMGAMSIMGAM2FGFR1
SCHEMBL16163330 0.80 MGAM (0.42) GAAMGAMSIMGAM2FGFR1
SCHEMBL24288007 0.80 JAK1 (0.32) SMN1; SMN2RAB9ATDP1MAPT
SCHEMBL20150091 0.80 TP53 (0.32) KDM4ESMN1; SMN2RAB9AALDH1A1TDP1
SCHEMBL20230856 0.80 P2RX7 (0.33) FGFR1FGFR2KDM4ESMN1; SMN2RAB9A
SCHEMBL3657985 0.78 STIM1 (0.49) KDM4ESMN1; SMN2RAB9AALDH1A1TP53
SCHEMBL15698575 0.77 ALDH1A1 (0.40) GAAMGAMSIMGAM2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060211739-A1 Use of selective P2X7 receptor antagonists ABBOTT LABORATORIES 2006-09-21 US disclosed
WO-2006086229-A1 THE USE OF SELECTIVE P2X7 RECEPTOR ANTAGONISTS ABBOTT LABORATORIES (US) 2006-08-17 WO disclosed
US-6143434-A HIGH LUMINANCE AND A HIGH LUMINESCENT EFFICIENCY AT A LOW DRIVING VOLTAGE AND HAS EXCELLENT STABILITY IN REPETITIONS OF USE FUJI PHOTO FILM CO., LTD. (JP) 2000-11-07 US disclosed
EP-0314104-B1 SILVER HALIDE PHOTOGRAPHIC MATERIALS FUJI PHOTO FILM CO., LTD. (JP) 1993-09-15 EP disclosed
US-5093222-A Contrast, negatives FUJI PHOTO FILM CO., LTD. (JP) 1992-03-03 US disclosed
EP-0314104-A2 Silver halide photographic materials FUJI PHOTO FILM CO., LTD. (JP) 1989-05-03 EP disclosed
US-4740455-A Heat developable light-sensitive material containing polymethine FUJI PHOTO FILM CO., LTD. (JP) 1988-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211739-A1 Use of selective P2X7 receptor antagonists P2RX1, P2RX3, P2RX7 GAA 4313/4885MGAM 4749/4885SI 4116/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.